Zura Bio's Veteran Leadership Eyes Repeat Success, Confident Analyst Sees 150% Upside
Portfolio Pulse from Vandana Singh
Raymond James initiated coverage on Zura Bio Limited (NASDAQ:ZURA) with a Strong Buy rating and a $20 price target. Zura has three clinical-stage inflammation & immunology drugs in development, licensed from Pfizer Inc (NYSE:PFE) and Eli Lilly And Co (NYSE:LLY). Zura Bio recently merged with JATT Acquisition Corp, raising $65 million in gross cash proceeds.
May 24, 2023 | 6:42 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Zura Bio licensed clinical-stage inflammation & immunology drugs from Eli Lilly And Co.
Although Zura Bio licensed drugs from Eli Lilly, the impact on Eli Lilly's stock price is likely to be minimal in the short term, as the licensing deal is just one of many business activities for the pharmaceutical giant.
CONFIDENCE 80
IMPORTANCE 40
RELEVANCE 50
NEUTRAL IMPACT
Zura Bio licensed clinical-stage inflammation & immunology drugs from Pfizer Inc.
While Zura Bio licensed drugs from Pfizer, the impact on Pfizer's stock price is likely to be minimal in the short term, as the licensing deal is just one of many business activities for the pharmaceutical giant.
CONFIDENCE 80
IMPORTANCE 40
RELEVANCE 50
POSITIVE IMPACT
Raymond James initiated coverage on Zura Bio with a Strong Buy rating and a $20 price target, indicating a potential 150% upside.
The Strong Buy rating and $20 price target from Raymond James indicate a positive outlook for Zura Bio's stock price in the short term. The company's recent merger and licensing deals with Pfizer and Eli Lilly also contribute to this positive sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100